[{"id":"6e2cb829-614d-4b97-bf37-e5a6143aeb0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05842785","created_at":"2023-05-06T15:04:03.887Z","updated_at":"2024-07-02T16:35:09.249Z","phase":"Phase 1/2","brief_title":"TSN222 in Subjects With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT05842785","lead_sponsor":"Tyligand Bioscience (Shanghai) Limited","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TSN222"],"overall_status":"Recruiting","enrollment":" Enrollment 162","initiation":"Initiation: 07/26/2023","start_date":" 07/26/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-04-17"}]